HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Immunotherapy adoption in community setting hindered by costs, biomarker identification
• Pediatric melanoma: Occurrence is rare, yet most common type of skin cancer in children
• Substantial physician shortage expected over next decade
• The language of cancer: ‘Battle words’ can have unintended consequences
• Recent data on management of cancer in pregnant women may be cause for optimism John Sweetenham, MD, FRCP, FACP
• FDA approves Keytruda for advanced NSCLC
• FDA approves Opdivo plus Yervoy for BRAF V600 wild-type melanoma
• FDA approves Optune for newly diagnosed glioblastoma multiforme
• FDA expands approval of Opdivo for advanced nonsquamous NSCLC
• FDA grants breakthrough therapy designation to abemaciclib for breast cancer
• FDA grants fast track designation to CF102 for HCC
• FDA grants fast track designation to DTX101 for hemophilia B
• FDA grants orphan drug designation to avelumab for Merkel cell carcinoma
• FDA grants orphan drug designation to BLU-554 for HCC
• FDA grants priority review to alectinib for ALK-positive lung cancer
• FDA grants priority review to Arzerra for maintenance therapy in relapsed CLL
• FDA grants priority review to defibrotide for hepatic veno-occlusive disease
• FDA grants priority review to expanded use of Kyprolis for relapsed myeloma
• FDA grants priority review to Halaven for advanced soft tissue sarcoma
• FDA grants priority review to ixazomib for relapsed, refractory multiple myeloma
• FDA grants priority review to rociletinib for advanced NSCLC
• AEGEAN: Adherence program does not provide additional value to apixaban users
• Alcohol consumption significantly increases risk for injury, cancer
• Algorithm may improve reporting of mortality after allogeneic HSCT
• Antiplatelet, anticoagulant therapy may lead to earlier bladder cancer diagnosis
• Aspirin reduces increased CRC risk associated with obesity, Lynch syndrome
• Brentuximab vedotin induces responses among older patients with Hodgkin’s lymphoma
• Canada's lung cancer screening program appears cost-effective
• Cardiorespiratory fitness levels predict risk for cancer diagnosis, mortality
• Delayed cord clamping safe, effective for very preterm infants
• Eculizumab appears safe, effective for pregnant women with PNH
• End-of-life care may be too intense among AYA patients with advanced cancer
• Enterovirus infections may reduce risk for leukemia in children
• Hedgehog signaling inhibitors show promise for basal cell carcinoma
• Higher quality screening colonoscopies reduce colorectal cancer incidence, death without higher costs
• HIV increases risk for death from common cancers
• ICD-10 transition likely ‘bumpy’ into early 2016
• Imetelstat demonstrates clinical activity for myelofibrosis, but may cause myelosuppression
• Interaction between prostate cancer, comorbidities increases VTE risk
• Molecular surgical margin assessment may predict recurrence in head and neck cancers
• Noncompliance has lessened efficacy of cervical cancer screening
• Older patients, women face greater risk for emergency cancer diagnosis
• Pediatric protocols applicable for adult patients with metastatic medulloblastoma
• Prevalence of germline BRCA mutations 5% in patients with pancreatic adenocarcinoma
• Recombinant FVIII with extended half life safe, effective for hemophilia A
• Results of repeat thyroid FNA mostly unchanged from initial biopsy
• Risk protocol identifies patients with cancer not allergic to carboplatin, oxaliplatin
• Selective reporting of primary, secondary endpoints common in randomized oncology trials
• Simulation model provides more accurate estimate of cancer progression in Barrett's esophagus
• Smokeless tobacco accounts for 250,000 deaths annually worldwide
• Splanchnic venous thrombosis a marker of occult cancer
• Statins may lower mortality risk in patients with lung cancer
• Survival gains in patients with mCRC only partially attributed to novel chemotherapies
• TAELE safer, more effective than TACE for HCC
• Urine biomarkers accurately identify early-stage pancreatic cancer
• Vosaroxin may improve outcomes for older patients with relapsed, refractory AML
• Younger first-degree relatives of colorectal cancer patients less likely to have colonoscopy
• American-Italian Cancer Foundation presents research prize
• ASH presents research grants to seven fellows
• Biostatistician joins Roswell Park Cancer Institute
• Bone marrow transplant surgeon named to Atlantic Council
• City of Hope announces several appointments
• Cleveland Clinic announces two appointments
• Fox Chase surgeon elected to society
• Immunologist wins medal of honor
• Penn researcher receives NCI Outstanding Investigator Award
• SUNY Downstate names division chief
• ASCO, AAHPM issue guidance statement on hospice, palliative care in oncology practice
• Cancer treatment during pregnancy does not affect pediatric outcomes
• Consulting services increase radiation receipt, reduce hospital stays for bone metastases
• Dual pathway inhibition prolongs advanced melanoma survival beyond 2 years
• Everolimus prolongs PFS for lung, GI neuroendocrine tumors
• Gene assay identifies women who can be spared chemotherapy for breast cancer
• Nivolumab prolongs OS in patients with nonsquamous NSCLC
• Primary tumor, lymph node biopsies do not detect targetable mutations of brain metastases
• Risk for DCIS recurrence has declined over time
• Spirituality, religiosity increased quality of life among patients with cancer